STAT+: Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone…
Category: weight loss
STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy,…
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a…
STAT+: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?
Hims & Hers, one of the largest publicly traded telehealth companies in the country, has…
Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug…
STAT+: Lilly launches Zepbound vials in move that could ease supply constraints
Eli Lilly said Tuesday that it will start providing low-dose vials of its obesity drug…
Does Ozempic increase the risk of suicidal thoughts? A new study muddles the picture
A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal…
STAT+: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?
On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building…
STAT+: Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales
Eli Lilly raised its full-year revenue guidance by $3 billion, driven by massive sales of…
STAT+: Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug…
STAT+: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs
Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are…
STAT+: Zealand’s amylin-targeting drug shows early potential in obesity
Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates…
STAT+: Biotech co-founded by entrepreneur Bob Langer is testing a new approach to developing obesity treatments
A new company founded by a group of biotech veterans, including Bob Langer, came out…
STAT+: Structure Therapeutics oral GLP-1 drug led to weight loss in two studies
Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two…
.jpg)
Wegovy linked to lower risk of alcohol use disorder in real-world study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease
Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type…
STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign
WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him….